×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [7]
湖南大学 [3]
内容类型
期刊论文 [10]
发表日期
2021 [1]
2019 [7]
2018 [2]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共10条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold
期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 卷号: 64, 期号: 9, 页码: 6161-6178
作者:
Xiong, Chaodong
;
Zhou, Lina
;
Tan, Jing
;
Song, Shanshan
;
Bao, Xubin
收藏
  |  
浏览/下载:32/0
  |  
提交时间:2021/08/17
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met
期刊论文
CANCER SCIENCE, 2019, 页码: 11
作者:
Tong, Mengya
;
Gao, Mingzhao
;
Xu, Yongping
;
Fu, Li
;
Li, Yun
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2020/07/01
AZD9291
c-Met ADC
c-Met overexpression
resistance
SHR-A1403
Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
期刊论文
CANCER SCIENCE, 2019, 页码: 9
作者:
Gao, Mingzhao
;
Zhu, Hongmei
;
Fu, Li
;
Li, Yun
;
Bao, Xubin
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2020/07/01
AG-221
IDH2
leukemia
R140Q
R172K
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models
期刊论文
CANCER SCIENCE, 2019, 卷号: 110, 期号: 4, 页码: 1420-1430
作者:
Long, Fei
;
He, Ye
;
Fu, Haoyu
;
Li, Yun
;
Bao, Xubin
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2020/07/01
breast cancer
CDK 4/6
drug resistance
palbociclib
SHR6390
Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials
期刊论文
CANCER SCIENCE, 2019, 卷号: 110, 期号: 3, 页码: 1064-1075
作者:
Wang, Lei
;
Yang, Changyong
;
Xie, Chengying
;
Jiang, Jiahua
;
Gao, Mingzhao
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2020/07/01
antitumor activity
fluzoparib
pharmacokinetics
poly(ADP-ribose) polymerase
toxicity
Pharmacologic characterization of fluzoparib, a novel poly polymerase inhibitor undergoing clinical trials
期刊论文
Cancer Science, 2019, 卷号: Vol.110 No.3, 页码: 1064-1075
作者:
Lei Wang
;
Changyong Yang
;
Chengying Xie
;
Jiahua Jiang
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2019/12/13
antitumor activity
fluzoparib
pharmacokinetics
poly(ADP‐ribose) polymerase
toxicity
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
期刊论文
Cancer science, 2019
作者:
Fei Long
;
Ye He
;
Haoyu Fu
;
Yun Li
;
Xubin Bao
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2019/12/17
CDK
4/6
SHR6390
breast
cancer
drug
resistance
palbociclib
Pharmacologic Characterization of Fluzoparib, a Novel Poly polymerase Inhibitor Undergoing Clinical Trials.
期刊论文
Cancer science, 2019
作者:
Lei Wang
;
Changyong Yang
;
Chengying Xie
;
Jiahua Jiang
;
Mingzhao Gao
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2019/12/13
PARP
Antitumor
activity
Fluzoparib
Pharmacokinetics
Toxicity
Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist
期刊论文
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 卷号: 22, 期号: 11, 页码: 5367-5377
作者:
Xie, Chengying
;
Zhao, Huajun
;
Bao, Xubin
;
Fu, Haoyu
;
Lou, Liguang
收藏
  |  
浏览/下载:34/0
  |  
提交时间:2019/01/08
eltrombopag
hetrombopag
hollow-fibre assay
thrombopoietin
thrombopoietin receptor
Combined inhibition of PI3K delta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia
期刊论文
CANCER LETTERS, 2018, 卷号: 420, 页码: 49-59
作者:
He, Ye
;
Sun, Liping
;
Xu, Yongping
;
Fu, Li
;
Li, Yun
收藏
  |  
浏览/下载:34/0
  |  
提交时间:2019/01/08
Acute myeloid leukemia
FLT3
PI3K delta
CAL101
Synergistic effect
©版权所有 ©2017 CSpace - Powered by
CSpace